Penumbra

Penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. We design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system.

Company Growth (employees)
Type
Public
HQ
Alameda, US
Founded
2004
Size (employees)
1,500 (est)
Penumbra was founded in 2004 and is headquartered in Alameda, US

Penumbra Office Locations

Penumbra has offices in Alameda, New York, Jersey, Berlin and in 4 other locations
Alameda, US (HQ)
1351 Harbor Bay Pkwy
Show all (8)

Penumbra Financials and Metrics

Penumbra Financials

Penumbra's revenue was reported to be $263.3 m in FY, 2016
USD

Revenue (Q2, 2017)

80.6 m

Gross profit (Q2, 2017)

50.9 m

Gross profit margin (Q2, 2017), %

63%

Net income (Q2, 2017)

(1.6 m)

EBIT (Q2, 2017)

(1.3 m)

Market capitalization (13-Nov-2017)

3.9 b

Cash (30-Jun-2017)

76.6 m
Penumbra's current market capitalization is $3.9 b.
USDFY, 2015FY, 2016

Revenue

186.1 m263.3 m

Revenue growth, %

41%

Cost of goods sold

62 m92.5 m

Gross profit

124.1 m170.8 m
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

50.4 m57.9 m65.1 m67.2 m73.2 m80.6 m

Cost of goods sold

16.9 m18 m23.6 m24.3 m25.5 m29.7 m

Gross profit

33.5 m39.9 m41.5 m42.9 m47.7 m50.9 m

Gross profit Margin, %

66%69%64%64%65%63%
USDFY, 2015FY, 2016

Cash

19.5 m13.2 m

Accounts Receivable

57.2 m47.7 m

Inventories

56.8 m73 m

Current Assets

244.4 m263.8 m
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

159.1 m17.6 m13.9 m15.9 m109.4 m76.6 m

Inventories

50.3 m66.6 m68.4 m70.1 m79.2 m81.1 m

Current Assets

249.1 m253.7 m260.3 m267.2 m372.4 m364.7 m

PP&E

8.6 m9.7 m11.9 m16.2 m22.9 m24.4 m
USDFY, 2015FY, 2016

Net Income

2.4 m14.8 m

Depreciation and Amortization

1.8 m2.3 m

Accounts Receivable

(11.1 m)(14.6 m)

Inventories

(25.1 m)(19.7 m)
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

732 k780 k185 k(1.1 m)(3.1 m)

Depreciation and Amortization

1.2 m

Accounts Receivable

(7.4 m)

Inventories

(18 m)66.6 m68.4 m70.1 m79.2 m
Y, 2017

Financial Leverage

1.1 x
Show all financial metrics

Penumbra Market Value History

Penumbra's Web-traffic and Trends

Penumbra News and Updates

Neurovascular Devices Market will achieve moderate growth to cross $2.3 billion by 2024

Latin America, driven by Brazil neurovascular device market share, followed by Asia Pacific will witness fastest growth, estimated to be over 5.5%, due to higher prevalence rate of brain aneurysm. Posted via Industry Today. Follow us on Twitter @IndustryToday

Penumbra Company Life and Culture

You may also be interested in